Multidimensional biomarker predicts disease control
Cofactor Genomics,
In response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma
In response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma
The immunotherapy nivolumab has today been made available on the Cancer Drugs Fund (CDF) for patients with head and neck cancer…
The immunotherapy nivolumab is kinder than chemotherapy for people with advanced head and neck cancer – easing many of the…